BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Li H. Angiogenesis in the progression from liver fibrosis to cirrhosis and hepatocelluar carcinoma. Expert Rev Gastroenterol Hepatol 2021;15:217-33. [PMID: 33131349 DOI: 10.1080/17474124.2021.1842732] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Shu X, Sun H, Yang X, Jia Y, Xu P, Cao H, Zhang K. Correlation of effective hepatic blood flow with liver pathology in patients with hepatitis B virus. Liver Research 2021;5:243-50. [DOI: 10.1016/j.livres.2021.11.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Garbuzenko DV. Pathophysiological mechanisms of hepatic stellate cells activation in liver fibrosis . World J Clin Cases 2022; 10(12): 3662-3676 [DOI: 10.12998/wjcc.v10.i12.3662] [Reference Citation Analysis]
3 Zhang J, Wang H, Yao L, Zhao P, Wu X. MiR-34a promotes fibrosis of hepatic stellate cells via the TGF-β pathway. Ann Transl Med 2021;9:1520. [PMID: 34790726 DOI: 10.21037/atm-21-5005] [Reference Citation Analysis]
4 Li Q, Kang H, Zhang R, Guo Q. Non-invasive precise staging of liver fibrosis using deep residual network model based on plain CT images. Int J Comput Assist Radiol Surg 2022;17:627-37. [PMID: 35194737 DOI: 10.1007/s11548-022-02573-8] [Reference Citation Analysis]
5 Yang H, Liu Y, Zhao MM, Guo Q, Zheng XK, Liu D, Zeng KW, Tu PF. Therapeutic potential of targeting membrane-spanning proteoglycan SDC4 in hepatocellular carcinoma. Cell Death Dis 2021;12:492. [PMID: 33990545 DOI: 10.1038/s41419-021-03780-y] [Reference Citation Analysis]
6 Wang S, Tang C, Zhao H, Shen P, Lin C, Zhu Y, Han D. Network Pharmacological Analysis and Experimental Validation of the Mechanisms of Action of Si-Ni-San Against Liver Fibrosis. Front Pharmacol 2021;12:656115. [PMID: 34276360 DOI: 10.3389/fphar.2021.656115] [Reference Citation Analysis]